GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists in Children and Adolescents with Obesity: Clinical Outcomes and the Impact of Nutritional and Behavioral Co-Interventions-A Systematic Review.

TL;DR

GLP-1 receptor agonists produce meaningful weight loss in children and adolescents (up to 16% BMI reduction with semaglutide), but the evidence is muddled by inconsistent reporting of lifestyle interventions, making it impossible to determine how much weight loss comes from the drug versus diet and behavioral changes.

What the study found

A systematic review of 15 studies involving 1,448 young people with obesity examined how GLP-1 receptor agonists (drugs originally designed for type 2 diabetes) perform when used off-label for weight management in children and adolescents aged 6 to 19 years. The analysis included trials of six different medications: liraglutide, exenatide, semaglutide, dulaglutide, tirzepatide, and lixisenatide. Across studies lasting 6 to 68 weeks, BMI reductions varied considerably, with semaglutide trials showing the largest effects at up to 16.1% reduction.

The weight loss itself is substantial and consistent across most agents tested. What emerged as the core problem, however, was not whether these drugs work, but rather that nearly all included studies paired the medication with some form of lifestyle intervention: dietary counseling, physical activity programs, behavioral therapy, or family-based support. The catch is that researchers almost never reported these co-interventions consistently or in enough detail to understand their scope, intensity, or structure. Some trials described "general dietary advice." Others mentioned "structured multidisciplinary programs." A few provided no meaningful detail at all.

This inconsistency created a methodological dead zone. When a child loses 16% of their BMI while taking semaglutide and attending a nutritional counseling program with weekly exercise supervision, how much of that loss came from the drug, and how much from the lifestyle changes? The review could not answer this question. The heterogeneity in study design and reporting made it impossible to isolate the independent contribution of either component. This is not a minor technical issue: understanding the separate effects of medication and behavior is essential for clinical decision-making, cost-benefit analysis, and determining what combination of interventions works best for individual patients.

The authors noted that standardized reporting protocols exist (like the TIDieR checklist, designed precisely to capture intervention details reproducibly) but are rarely applied in this literature. Future pediatric GLP-1 trials need to adopt these standards, use factorial or stratified randomization designs to test lifestyle intensity separately from pharmacotherapy, and incorporate validated measures of eating behavior and dietary intake. Without these changes, the field will continue to accumulate efficacy data while remaining unclear about mechanism and attribution.

What this means for you

If you are a parent or guardian considering GLP-1 drugs for a young person with obesity, understand that the weight loss shown in these trials is real, but the true role of concurrent lifestyle work remains unquantified. This does not mean the drugs don't work; it means the research doesn't yet tell you cleanly how much benefit comes from medication alone versus the full package.

Practically, this suggests treating pharmacotherapy and behavioral intervention as potentially independent levers: the drug may reduce appetite and metabolic demand, but dietary changes, regular physical activity, and behavioral modification are supported by separate evidence and merit attention regardless. A clinician prescribing a GLP-1 agonist should not interpret the trial data as implying that the drug alone will produce the reported weight loss; the lifestyle context matters and remains underspecified.

For researchers and clinical teams, the takeaway is clear: future trials must separate the wheat from the chaff. Standardize how lifestyle interventions are described and delivered. Use study designs that allow measurement of both the drug effect and the behavioral effect. Validate the tools used to measure dietary intake and eating behavior change. Only then will we know whether these medications are doing most of the work, or whether they are potentiating effects that depend equally on behavior change.

Study details

Sources

Systematic Review: GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists in Children and Adolescents with Obesity. Nutrients. 2025. PubMed: 42280306